IN THE SPOTLIGHT

Dana-Farber Cancer Institute Inc Files Patent Application for Allosteric EGFR Inhibitors and Methods of Use Thereof

Dana-Farber Cancer Institute Inc Files Patent Application for Allosteric EGFR Inhibitors and Methods of Use Thereof

Sequential targeted therapy in synchronous dual-primary lung adenocarcinomas with EGFR and RET alterations: a 5-year follow-up case report

Sequential targeted therapy in synchronous dual-primary lung adenocarcinomas with EGFR and RET alterations: a 5-year follow-up case report

Estimand Framework Development for eGFR Slope Estimation and Comparative Analyses Across Various Estimation Methods

Estimand Framework Development for eGFR Slope Estimation and Comparative Analyses Across Various Estimation Methods

Promatix Biosciences Presents Positive Preclinical Data with First-in-Class PBS293 EGFR×EphA2 Cis-Bispecific ADC Demonstrating Enhanced Tumour Selectivity

Promatix Biosciences Presents Positive Preclinical Data with First-in-Class PBS293 EGFR×EphA2 Cis-Bispecific ADC Demonstrating Enhanced Tumour Selectivity

B7-H3-mediated cis-inhibition of EGFR by a tumor-selective bispecific antibody enhances anti-tumor efficacy and minimizes toxicities

B7-H3-mediated cis-inhibition of EGFR by a tumor-selective bispecific antibody enhances anti-tumor efficacy and minimizes toxicities

Johnson & Johnson : Subcutaneous RYBREVANT®▼ (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell lung cancer

Johnson & Johnson : Subcutaneous RYBREVANT®▼ (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell lung cancer

Clinical outcomes and survival in patients with NSCLC and EGFR exon 20 mutations: evidence from real-world clinical practice in a retrospective study in Galicia

Clinical outcomes and survival in patients with NSCLC and EGFR exon 20 mutations: evidence from real-world clinical practice in a retrospective study in Galicia

Advancing EGFR Ex20 Insights With Catherine Shu – IASLC

Advancing EGFR Ex20 Insights With Catherine Shu – IASLC